Trevi Therapeutics IncTRVI
Price$14.32

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$51.1MTTM through 30 Jun 2026
Free Cash Flow -$52.9MTTM through 30 Jun 2026

Margins

Current

Returns

-26.5%ROE
-15.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio23.50x
Net Debt-$171.8Mnet cash position
Cash & Equivalents$54.3M

Quality Metrics

Altman Z-Score143.59
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$0.35TTM
'21'22'23'24'25
FY2025: $-0.32

Dividend

No dividend

Capital Allocation

R&D Spend$41.4M

Segment Performance

SegmentRevenueYoYOutlook
Haduvio (nalbuphine ER) Development$0
View details

Topline results from Phase 3 trials expected in H2 2027 and H1 2028; Phase 2b RCC topline results expected in H2 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.